Whether PPARδ activation in immune cells versus cancer cells differentially controls antitumor immunity and immunotherapy efficacy, studied using compartment-specific genetic gain- and loss-of-function mouse models, human patient-derived organoid co-cultures, and human CAR-T cell systems across microsatellite stable (MSS) and microsatellite instable (MSI) colorectal cancer and other tumor types.
Immune-specific PPARδ activation suppressed tumor growth across MSI and MSS models, overriding pro-tumorigenic effects of cancer-cell PPARδ; in mice bearing MSS metastatic CRC (AKPS), adoptive transfer of PPARδ-activated CD8+ T cells plus anti-PD-1 led to 50% complete tumor rejection, significant metastasis reduction (2/13 vs 8/11 in controls), and improved survival with combined checkpoint blockade (p=0.0121). Pharmacological (GW501516) or genetic PPARδ activation also enhanced human EGFR- and HER-2-targeting CAR-T cell cytotoxicity in vitro and in vivo.
All in vivo findings are in preclinical mouse models; the VP16/VP64 constitutively active fusion does not fully replicate native ligand-dependent PPARδ biology and may not capture transrepression effects. Adoptive transfer experiments required lymphodepleting irradiation, which could confound outcomes. Long-term safety of immune-specific PPARδ activation was not assessed beyond the observation period, and no sex-stratified or clinical human trial data are presented.
Selectively activating PPARδ in immune cells—rather than systemically—could enhance CD8+ T cell fitness and sensitize immunotherapy-resistant MSS colorectal cancer to checkpoint blockade; this principle may guide development of metabolic preconditioning strategies for adoptive cell therapies such as CAR-T cells in solid tumors.